Rett Syndrome: Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Rett Syndrome therapeutics.
In the 16 countries covered in GlobalData’s epidemiology forecast for Rett syndrome (RS), there are projected to be 97,327 diagnosed prevalent cases of RS in 2024, decreasing to 93,614 by 2029.
Treatment guidelines for RS are still evolving but are generally well-defined for symptom management and multidisciplinary care.
There are 51 molecules in development for RS, with only one drug in the pre-registration stage-trofinetide, which is already approved in the US and is being developed in the EU in Phase III.
A total of 42 clinical trials were initiated for RS in the last 10 years. The highest number of trials for RS were initiated in 2019, with nine trials, followed by 2023 with six trials.
In deals involving companies with RS assets, licensing agreements were the predominant deal type in the Asia-Pacific region, while partnerships dominated in North America and Africa. In Europe, acquisitions, partnerships, and licensing agreements were evenly distributed.
Scope
GlobalData’s Rett Syndrome: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook